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The total serum concentration of 25-hydroxyvitamins D (25-hydroxyvitamin D3 and 25-hydroxyvitamin
D2) is currently used as an indicator of vitamins D status. Vitamins D insufﬁciency is claimed to be
associated with multiple diseases, thus accurate and precise reference methods for the quantiﬁcation
of 25-hydroxyvitamins D are needed. Here we present a novel enzyme-assisted derivatisation method
for the analysis of vitamins D metabolites in adult serum utilising 25-[26,26,26,27,27,27-2H6]hydroxyvi-
tamin D3 as the internal standard. Extraction of 25-hydroxyvitamins D from serum is performed with
acetonitrile, which is shown to be more efﬁcient than ethanol. Cholesterol oxidase is used to oxidize
the 3b-hydroxy group in the vitamins D metabolites followed by derivatisation of the newly formed 3-
oxo group with Girard P reagent. 17b-Hydroxysteroid dehydrogenase type 10 is shown to oxidize selec-
tively the 3a-hydroxy group in the 3a-hydroxy epimer of 25-hydroxyvitamin D3. Quantiﬁcation is
achieved by isotope-dilution liquid chromatography–tandem mass spectrometry. Recovery experiments
for 25-hydroxyvitamin D3 performed on adult human serum give recovery of 102–106%. Furthermore in
addition to 25-hydroxyvitamin D3, 24,25-dihydroxyvitamin D3 and other uncharacterised dihydroxy
metabolites, were detected in adult human serum.
 2014 The Authors. Published by Elsevier Inc. Open access under CC BY license.1. Introduction B ring between carbons 9 and 10 [1]. As in oxysterols the conﬁgu-Vitamin D2 and D3 belong to the class of secosteroids which,
compared to common steroids are characterised by having an openration around the C-5–C-6 double bond is Z (Fig. 1A). Ultra violet
(UV) B light from the sun causes the formation of vitamin D3 from
7-dehydrocholesterol in the upper dermis layers of the skin [1–5].
Vitamin D2 is formed in plants and fungi following photolysis of
ergosterol by UV irradiation and appears in dietary supplements
and fortiﬁed foods [1,4]. Vitamins D3 and D2 are metabolized in
the liver by cytochochrome P450 (CYP) enzymes to 25-hydroxyvi-
tamin D3 (25-OHD3) and D2 (25-OHD2), respectively. 25-Hydrox-
yvitamins D are further metabolized, primarily in the kidney, but
also in other target tissues to their active metabolites 1a,25-
dihydroxyvitamin D3 (1a,25-(OH)2D3) and D2 (1a,25-(OH)2D2)
and the metabolites 24,25-dihydroxyvitamin D3 (24,25-(OH)2D3)
and D2 (24,25-(OH)2D2) [1].
Insufﬁciency in vitamins D is claimed to be associated with
diseases such as cardiovascular disease, hypertension, diabetes,
cancer, skin disorders and autoimmune disease [2,3,6]. Due to
the recent increase in numbers of vitamins D analysis performed
worldwide there is a need for accepted reference methods for
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Fig. 1. (A) Overview of the enzyme-assisted derivatisation method for 25-OHD3. (B) MS2 and MS3 fragmentation pathways for 25-OHD3.
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indicators of vitamins D status [4]. Liquid chromatography (LC)
offers separation of 25-OHD2 and 25-OHD3 from each other
and from much matrix interference, including isobaric interfer-
ences from e.g. the endogenous 3a-hydroxy epimer of 25-
OHD3 (3-epi-25-OHD3) [7,8]. Use of isotope dilution mass spec-
trometry (MS) typically further limits matrix effects and im-
proves precision and accuracy [8]. LC–MS has been proposed
as the ‘‘gold standard’’ for quantiﬁcation of 25-hydroxyvitamins
D in serum [8]. Within the last ten years LC–MS has grown in
use and today about 11% of clinical laboratories use LC–MS for
vitamins D analysis [7,8]. Currently there are two procedures
based on LC–MS which have been accepted as reference method
procedures by the Joint Committee for Traceability in Laboratory
Medicine [9,10].
The aim of this report is to introduce a novel procedure for
quantiﬁcation of 25-OHD3 in adult human serum, which in-
volves enzyme-assisted derivatisation with cholesterol oxidase
and derivatisation with Girard P (GP) reagent. As vitamin D2
is used pharmaceutically to treat vitamins D deﬁciency mostly
in the USA, and the adult human serum analysed in this study
originated from the UK, 25-OHD2 was not included in our stud-
ies [2]. The new method offers improved sensitivity and most
importantly speciﬁcity for vitamins D analysis compared to
the two current reference methods [9,10]. Brieﬂy the method
involves oxidation of the 3b-hydroxy group of 25-OHD3 with
cholesterol oxidase followed by derivatisation of the newly
formed 3-oxo group with GP reagent (Fig. 1A). The method is
a modiﬁcation of the published protocol for oxysterol analysis
[11,12].2. Materials and methods
25-OHD3 was from Standard Reference Material (SRM) 2972
from the National Institute of Standards and Technology (NIST,
Gaithersburg, Maryland, USA). It was dissolved in ethanol at a cer-
tiﬁed concentration of 846.0 nmol/L (338.9 ng/mL). 3-Epi-25-OHD3
(P98% chemical purity) in ethanol at 100 lg/mL was purchased
from Sigma–Aldrich (Dorset, UK). 1a,25-(OH)2D3 and 24,25-
(OH)2D3 were from Sigma–Aldrich. The internal standard 25-
[26,26,26,27,27,27-2H6]hydroxyvitamin D3 ([2H6]25-OHD3) was
from Medical Isotopes, Inc. (Pelham, NH, USA) and was of chemical
and isotopic purity >99% and >98%, respectively. Cholesterol
oxidase from Streptomyces sp, glutathione S-transferase tagged
human 17b-hydroxysteroid dehydrogenase 10 (17bHSD10) and
b-nicotinamide adenine dinucleotide (b-NAD+) hydrate were from
Sigma–Aldrich (Dorset, UK). GP reagent [1-(carboxymethyl)pyridi-
nium chloride hydrazide] was purchased from TCI Europe (Oxford,
UK). [2H5]GP reagent was synthesised in house. Solid phase extrac-
tion (SPE) cartridges, Certiﬁed Sep-Pak C18, 200 mg (3 cm3), and
60 mg Oasis HLB (3 cm3), were from Waters Inc. (Elstree, UK). Sol-
vents were obtained from Fisher-Scientiﬁc (Loughborough, UK).
Acetic acid and formic acid were of AnalaR NORMAPUR grade
(BDH, VWR, Lutterworth, UK). Potassium dihydrogen phosphate
and potassium pyrophosphate decahydrate were from Sigma–
Aldrich.
Stock solutions of 1a,25-(OH)2D3 and 24,25-(OH)2D3 were pre-
pared by dissolving 100 lg in 1 mL of absolute ethanol (100 ng/lL).
A stock solution of [2H6]25-OHD3 was prepared by dissolving
1.70 mg in 17 mL absolute ethanol (100 ng/lL). All stock solutions
were stored in the dark. Working solutions (1 ng/lL) were made
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solution in 990 lL of absolute ethanol.
2.1. Procedure
2.1.1. Sample preparation
Sample preparation of serum was largely performed as previ-
ously described [12]. In brief, 100 lL of serum was added drop-
wise to a solution of acetonitrile (1.05 mL) containing 1 ng of
[2H6]25-OHD3. After 10 min sonication in an ultrasonic bath the
solution was centrifuged at 14,000g at 4 C for 30 min. The super-
natant was dried under vacuum using a ScanLaf ScanSpeed vac-
uum concentrator and reconstituted in 1.05 mL of absolute
ethanol and sonicated for 15 min. Water (0.45 mL) was added
dropwise and ultrasonication continued for a further 5 min. The ﬁ-
nal sample solution of 1.5 mL 70% ethanol was loaded onto a
200 mg Certiﬁed Sep-Pak C18 cartridge pre-conditioned with
4 mL of absolute ethanol and with 6 mL of 70% ethanol. The solvent
ﬂow through the column was at a rate of 0.25 mL/min assisted by
negative pressure at the column outlet generated by a vacuum
manifold (Agilent Technologies). The ﬂow-through (1.5 mL) was
combined with a column wash of 70% ethanol (5.5 mL) to give frac-
tion SPE1-Fr1 (7 mL). A second fraction (SPE1-Fr2) was collected by
eluting with a further 4 mL of 70% ethanol before fraction 3 con-
taining cholesterol was eluted with 2 mL of absolute ethanol
(SPE1-Fr3). Finally, a fourth fraction eluted with a second 2 mL of
absolute ethanol, (SPE1-Fr4). Each fraction was divided into two
equal fractions (A) and (B) and allowed to dry overnight under re-
duced pressure. Lyophilised material was reconstituted in 100 lL
of propanol-2-ol. The remainder of the procedure, oxidation with
cholesterol oxidase and GP derivatisation followed by SPE puriﬁca-
tion, was performed as previously described with the exception
that Sep-Pak C18 cartridges were replaced by Oasis HLB cartridges
[11–13].
2.1.2. LC–MS and MSn analysis
Analysis was performed on a LTQ-Orbitrap Velos (Thermo
Fisher Scientiﬁc, UK) equipped with an electrospray probe, and a
Dionex Ultimate 3000 LC system (Dionex, UK), essentially as de-
scribed by Grifﬁths et al. [12]. The only major difference was in
the MS3 events where in the current study we exploited the neutral
losses of 97.05 Da ([M]+? [M-Py-18]+?) rather than 79.04 Da
([M]+? [M-Py]+?) as 25-hydroxylated metabolites of vitamins D
lose water in addition to pyridine in the initial fragmentation event
(Fig. 1B) while oxysterols mostly lose pyridine [12].
2.1.3. Quantiﬁcation
Serum 25-OHD3 was quantiﬁed by stable isotope dilution LC–
MS against [2H6]25-OHD3 reference standard.
2.2. Optimisation of extraction
Acetonitrile and ethanol were compared in their ability to ex-
tract 25-OHD3 in serum. Performance of a single-step extraction
was compared against a two-step extraction i.e., re-extraction of
the pellet following the initial extraction. Extraction in acetonitrile
was performed as stated above while extraction in ethanol was
performed as described by Grifﬁths et al. [11,12]. The supernatant
generated by the second extraction was either combined with that
from the ﬁrst extraction or processed separately.
2.3. Recovery experiments
2.3.1. Standard addition of [2H6]25-OHD3
Known amounts of [2H6]25-OHD3 (2, 4 or 6 ng) were added to
100 lL of serum (batch DEQAS423, the endogenous level of 25-OHD3 was predetermined using 1 ng of internal standard), and ex-
tracted once using acetonitrile as described above. Each experi-
ment was performed in triplicate. Recovery was determined at
each concentration of added internal standard by dividing the
experimentally measured concentration ratio of 25-OHD3 to
[2H6]25-OHD3 with the theoretical concentration ratio (Eq. (1)) [9].
%Recovery ¼ 25-OHD3½ =½2H625-OHD3
 
exp=
n
½25-OHD3=½2H625-OHD3
 
theor
 100% ð1Þ2.3.2. Standard addition of 25-OHD3
A second recovery experiment was performed by adding known
amounts of 25-OHD3 (1, 2, 4 or 6 ng) to 100 lL serum (batch DE-
QAS424, the endogenous level of 25-OHD3 was predetermined),
and extracting once using acetonitrile. The internal standard
[2H6]25-OHD3 (1 ng) was added to each sample. Each experiment
was performed in triplicate. Recovery was determined at each con-
centration of added 25-OHD3 by dividing the experimentally mea-
sured serum concentration of 25-OHD3 with the theoretical
concentration (Eq. (2)) [9].
%Recovery ¼ 25-OHD3½ exp=½25-OHD3theor
n o
 100% ð2Þ2.4. Selective derivatisation of 3-epi-25-OHD3
Oxidation of 400 ng of 3-epi-25-OHD3 or 25-OHD3 by
17bHSD10 was essentially performed as described in the literature
for steroid hormones and bile acids [14,15]. 30 mg of b-NAD+ was
dissolved in 1 mL of 100 mM pyrophosphate buffer pH 8.9. 3-Epi-
25-OHD3 or 25-OHD3 dissolved in ethanol was added (10 lL), giv-
ing a ﬁnal concentration of 1% ethanol. Finally 1 lg of 17bHSD10
was added, giving an enzyme concentration of 1 lg/mL. After incu-
bation at room temperature for 24 h, 40 lL of methanol was added
(content of organic solvent is now 5%). The mixture, followed by a
0.5 mL rinse (5% methanol) of the reaction tube, was loaded on a
60 mg HLB cartridge previously washed with 6 mL of methanol
and conditioned 6 mL of 5% methanol. The loaded cartridge was
washed with 6 mL of 5% methanol. Elution of secosterols was per-
formed with 2 mL of methanol into which 1 mL of water was added
to make the solution 67% methanol and quenching any residual
enzyme activity [11–13]. Glacial acetic acid (150 lL) was then
added followed by GP reagent (150 mg) and the mixture left at
room temperature overnight. Finally SPE recycling on a 60 mg
Oasis HLB cartridges to remove excess derivatisation reagent was
carried out as described previously [11–13]. LC–MSn analysis was
performed as described above (Section 2.1.2).
3. Results and discussion
3.1. General considerations related to the methodology
GP derivatisation of 25-OHD3 provides multiple advantages
including increased solubility in mobile phases commonly used
for LC–MS, enhanced ionisation, characteristic fragmentation
patterns in MS2 i.e. loss of pyridine (Py) and water giving [M-Py-
18]+ ions (Fig. 1B), and structurally informative MS3 spectra
([M]+? [M-Py-18]+?) with particularly intense fragment ions at
m/z 189 for 25-OHD3 (Fig. 1B) and its side-chain oxidised metabo-
lites (Fig. 2E, F, H) or m/z 205 for 1,25-(OH)2D3 and its metabolites
(Fig. 2G). The current method, with speciﬁc fragment ions at m/z
189 and 205, provides advantages over other LC–MS/MS
procedures based on the loss of water or other nonspeciﬁc frag-
mentations [9]. With respect to sensitivity, LC–MS analysis of GP-
derivatised 25-OHD3 in serum (16.54 ng/mL, on-column injection
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Fig. 2. LC–MS RIC ± 10 ppm appropriate to GP-derivatised (A) monohydroxyvitamin D3, (B) dihydroxyvitamin D3, authentic (C) 1,25-(OH)2D3 and (D) 25-OHD2. RIC shown in
(A) and (B) are for adult human serum, (C) and (D) are of authentic standards (25 pg on-column). GP-derivatives form syn and anti conformers about C-3 this is evident in (A)
where 25-OHD3 elutes in two peaks at 8.03 and 8.38 min, in (B) where 24,25-(OH)2D3 elutes at 5.93 and 6.31 min and in (D) where 25-OHD2 elutes at 8.35 and 8.70 min.
Shown in (E–H) are MS3 ([M]+? [M-Py-18]+?) spectra of GP-derivatised 25-OHD3, 24,25-(OH)2D3, 1a,25-(OH)2D3 and 25-OHD2. In this example [2H5]GP reagent was used.
Due to the presence of the 1a-hydroxy group in 1a,25-(OH)2D3 its major fragment in the low m/z range is m/z 205 rather than m/z 189 as seen for 25-OHD3, 24,25-(OH)2D3
and 25-OHD2. This agrees with the fragmentation pathway presented in Fig. 1B. The major unannotated peak in (B) corresponds to GP-derivatised 3b-hydroycholest-(25R)-5-
en-26-oic acid, a major component of human serum [12].
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A B
Fig. 3. (A) MS3 ([M+]? [M-Py-18]+?) TIC of 3-epi-25-OHD3 oxidized with 17bHSD10 and derivatised with GP reagent. (B) MS3 spectrum of 3-epi-25-OHD3-GP eluting at
8.45 min. As in Fig. 2 [2H5]GP reagent was used.
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(Fig. 2A). In comparison the limits of detection are 10 and 40 pg
on-column for the two current LC–MS reference methods [9,10].
By generating reconstructed-ion chromatograms (RIC) for the tran-
sitions [M]+? [M-Py-18]+?m/z 189 or 205 appropriate for dihy-
droxy metabolites of vitamin D3, the presence of possible vitamin
D3 metabolites eluting at 4.28, 5.39, 5.93, 6.31, and 6.64 min was
revealed (Fig. 2B). Analysis of an authentic standard of 24,25-
(OH)2D3 conﬁrmed the peaks at 5.93 and 6.31 min to be the syn/
anti conformers of 24,25-(OH)2D3.
Although the derivatisation protocol exploited here was origi-
nally developed for the analysis of oxysterols [11,12], we now
show that it is equally applicable to vitamins D metabolites. In
Fig. 2 we show the utility of the method to the analysis of the
secosterols, 25-OHD3 and 24,25-(OH)2D3 in adult human serum
and to 1,25-(OH)2D3 and 25-OHD2 standards. Thus, an open B ring
in secosterols does not prevent their oxidation by cholesterol
oxidase.
As 3-epi-25-OHD3 and 25-OHD3 only differ in the conﬁguration
of the 3-hydroxy group, following oxidation with cholesterol oxi-
dase then GP derivatisation their products are identical. Therefore
3-epi-25-OHD3 could interfere with the analysis of 25-OHD3. How-
ever, we ﬁnd that in 1 h incubations with cholesterol oxidase the
efﬁciency of oxidation of 3-epi-25-OHD3 is less than 10% that of
25-OHD3. As the adult serum concentration of 3-epi-25OHD3 is
typically only 4% that of 25-OHD3 [8], interference by 3-epi-25-
OHD3 will result in <1% overestimation of the serum concentration
of 25-OHD3. However, in cases where the presence of 3-epi-
25OHD3 is suspected (infants <1 year) its exact level can be deter-
mined using the enzyme 17bHSD10 (see Section 3.2 below), and by
incorporating the internal standard 3-epi-25-[6,19,19-2H3]OHD3
its relative contribution to the peak of GP derivatised 25-OHD3
can be determined.
3.2. Novel derivatisation of 3-epi-25-OHD3
17bHSD10 is a multifunctional enzyme capable of oxidizing
multiple steroids with 3a-, 7a-, 7b-, 17b-, 20b-, or 21-hydroxy
group if its cofactor, b-NAD+ is present [14–16]. Thus, 17bHSD10
could be an enzyme capable of oxidizing 3-epi-25-OHD3 (3a-hy-
droxy) but not 25-OHD3 (3b-hydroxy), thereby allowing selective
analysis of 3-epi-25-OHD3 following GP derivatisation. The biolog-
ical signiﬁcance if any of 3-epi-25-OHD3 remains to be elucidated,
but it contributes 9–61% of the total 25-hydroxyvitamins D in in-
fant (<1 year) sera [8]. Oxidation of authentic standards of 3-epi-
25-OHD3 and 25-OHD3 by 17bHSD10 followed by GP derivatisation
proved that the enzyme was capable of oxidizing 3-epi-25-OHD3(Fig. 3A and B), but no product of 25-OHD3 oxidation was observed.
Currently analytical methods in the literature rely on chromato-
graphic resolution of 3-epi-25-OHD3 from 25-OHD3 [8]. Use of
17bHSD10 to oxidize selectively 3-epi-25-OHD3 provides an alter-
native route for its speciﬁc analysis.3.3. Optimisation of extraction
In Supplementary Table S1 a comparison of the amounts of 25-
OHD3 recovered from adult serum using different extraction meth-
ods is given. Extraction with ethanol was less efﬁcient than with
acetonitrile. Two-step extraction with acetonitrile was no more
efﬁcient than a single extraction. The concentration of 25-OHD3
determined using the one-step acetonitrile extraction was
17.76 ± 0.79 ng/mL (mean ± SD), with a coefﬁcient of variation
(CV) of <5%. This agrees well with the value of 18.07 ng/mL certi-
ﬁed by NIST for the sample using their LC–MS reference method
[9].3.4. Recovery experiments
Supplementary Tables S2 and S3 show recovery data from
experiments exploiting standard addition of [2H6]25-OHD3
(102.0–106.3%) and of 25-OHD3 (101.2–104.9%), respectively, to
adult human serum. The within-batch precision was <6% in both
experiments.
In conclusion we report an LC–MSn method based on enzyme-
assisted derivatisation for the analysis of vitamins D metabolites,
including 3-epi-25-OHD3. In addition to being accurate and robust
in quantifying the serum level of adult 25-OHD3, diagnostic MS3
fragment ions ofm/z 189 and 205 conﬁrm the identiﬁcation of vita-
mins D metabolites.Acknowledgments
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